FDA grants special designation for Bayer AI software

Bayer announced in a release that the U.S. Food and Drug Administration granted a breakthrough device designation for an AI pattern recognition software that it is jointly developing with Merck. The software is designed for the treatment of chronic thromboembolic Pulmonary Hypertension (CTEPH), a rare form of pulmonary hypertension that is often difficult to diagnose because symptoms often mimic those of asthma or chronic obstructive pulmonary disease (COPD). Working together, Bayer and Merck have…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news